Cargando…
Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes
SIMPLE SUMMARY: The major histocompatibility complex class II-associated peptide proteomics assay is widely used during preclinical immunogenicity risk assessments to identify biotherapeutic-derived peptides. These potential T cell epitopes are presented by dendritic cells and may trigger CD4(+) T h...
Autores principales: | Hartman, Katharina, Steiner, Guido, Siegel, Michel, Looney, Cary M., Hickling, Timothy P., Bray-French, Katharine, Springer, Sebastian, Marban-Doran, Céline, Ducret, Axel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525474/ https://www.ncbi.nlm.nih.gov/pubmed/37759665 http://dx.doi.org/10.3390/biology12091265 |
Ejemplares similares
-
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
por: Siegel, Michel, et al.
Publicado: (2022) -
Response to Shusterman and to Mapp
por: Meggs, William
Publicado: (1994) -
Status of FASER and MAPP
por: Dozen, Candan
Publicado: (2021) -
NetCTLpan: pan-specific MHC class I pathway epitope predictions
por: Stranzl, Thomas, et al.
Publicado: (2010) -
MAPP Phase-1 Technical Proposal
por: Pinfold, J L
Publicado: (2021)